Quick Dispatch:
Your glp-1-directed nmda receptor antagonism for obesity treatment Targeting Obesity: GLP-1R, GIPR, GDF8 as Key Therapeutic Agents orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your glp-1-directed nmda receptor antagonism for obesity treatment Targeting Obesity: GLP-1R, GIPR, GDF8 as Key Therapeutic Agents ships.
Need Help?
Questions about glp-1-directed nmda receptor antagonism for obesity treatment Targeting Obesity: GLP-1R, GIPR, GDF8 as Key Therapeutic Agents, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for glp-1-directed nmda receptor antagonism for obesity treatment Targeting Obesity: GLP-1R, GIPR, GDF8 as Key Therapeutic Agents in your area.
Neurobiological Mechanisms and Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Binge Eating Disorder: A Narrative Review
26.54
Metabolic Flux Adaptations During GLP-1 Receptor Agonist Therapy: Redox Implications | Current Obesity Reports
24.98
Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies
22.29
Frontiers
29.05
Brain control of energy homeostasis: Implications for anti-obesity pharmacotherapy
21.16
Nutritional Care for Adults With Obesity Treated With Glucagon-Like Peptide (GLP)-1 and Dual Glucose-Dependent Insulinotropic Polypeptide (GIP)/GLP-1 Receptor Agonists: A Review of Evidence, Gaps, and Clinical Implications
21.62
Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism
25.14
